{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:08:09Z","timestamp":1766174889422,"version":"3.48.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.resmer.2025.101216","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:26:54Z","timestamp":1760074014000},"page":"101216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice"],"prefix":"10.1016","volume":"88","author":[{"given":"Christos","family":"Chouaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Stancu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Ano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Grela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Goyard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Fore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Magne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Pante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydie","family":"Lemonnier-Videau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Falchero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.resmer.2025.101216_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-020-01069-z","article-title":"The current treatment landscape in the UK for stage III NSCLC","volume":"123","author":"Evison","year":"2020","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.resmer.2025.101216_bib0002","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resmer.2025.101216_bib0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DDDT.S141491","article-title":"Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma","volume":"12","author":"Faiena","year":"2018","journal-title":"Drug Des Devel Ther."},{"issue":"2","key":"10.1016\/j.resmer.2025.101216_bib0004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.resmer.2025.101216_bib0005","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.resmer.2025.101216_bib0006","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.resmer.2025.101216_bib0007","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/1759-7714.14667","article-title":"Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Thorac Cancer"},{"issue":"8","key":"10.1016\/j.resmer.2025.101216_bib0008","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.3390\/curroncol30080559","article-title":"Real-world analysis of Durvalumab after chemoradiation in stage III non-small-cell lung cancer","volume":"30","author":"Preti","year":"2023","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.resmer.2025.101216_bib0009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received Durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.resmer.2025.101216_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.resmer.2025.101216_bib0011","article-title":"Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): results of three French consecutive nationwide prospective cohorts' studies","volume":"22","author":"Debieuvre","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"10.1016\/j.resmer.2025.101216_bib0012","doi-asserted-by":"crossref","first-page":"705","DOI":"10.21037\/tcr-23-52","article-title":"PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab","volume":"12","author":"K\u00e4smann","year":"2023","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.resmer.2025.101216_bib0013","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12890-025-03791-x","article-title":"PD-1\/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis","volume":"25","author":"Mao","year":"2025","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.resmer.2025.101216_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.resmer.2025.101216_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100410","article-title":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial","volume":"7","author":"Senan","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.resmer.2025.101216_bib0016","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.resmer.2025.101216_bib0017","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.resmer.2025.101216_bib0018","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.resmer.2025.101216_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113373","article-title":"A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study","volume":"195","author":"Yamada","year":"2023","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.resmer.2025.101216_bib0020","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.2217\/fon-2021-0952","article-title":"DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy","volume":"17","author":"Filippi","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.resmer.2025.101216_bib0021","doi-asserted-by":"crossref","first-page":"S1302","DOI":"10.1016\/j.annonc.2023.10.058","article-title":"LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): primary results from the DUART study","volume":"34","author":"Filippi","year":"2023","journal-title":"Ann Oncol"},{"issue":"10405","key":"10.1016\/j.resmer.2025.101216_bib0022","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.resmer.2025.101216_bib0023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/pds.5323","article-title":"Differential frequency in imaging-based outcome measurement: bias in real-world oncology comparative-effectiveness studies","volume":"31","author":"Adamson","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041225000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041225000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:04:51Z","timestamp":1766174691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041225000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S2590041225000637"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2025.101216","relation":{},"ISSN":["2590-0412"],"issn-type":[{"type":"print","value":"2590-0412"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2025.101216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SPLF and Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101216"}}